2. UroToday Home
  3. Trials in Progress

Trials in Progress

BOND-003 Cohort P Study of Cretostimogene Given in Patients With Non-Muscle Invasive Bladder Cancer, Unresponsive to BCG

Trials in Progress
Videos

A Phase 3 Study of Cretostimogene Grenadenorepvec in Patients With Non-Muscle Invasive Bladder Cancer (NMIBC) Unresponsive to Bacillus-Calmette-Guerin (BCG)

  • Condition: Non Muscle Invasive Bladder Cancer, High-grade Ta/ T1 Papillary Disease Bladder Cancer
  • Study ID: NCT04452591
View Trial
Conference Coverage
Conference Highlights Written by Physician-Scientist
Presented by Trinity Bivalacqua, MD, PhD,
The 2025 EAU annual meeting featured a non muscle invasive bladder cancer session and a presentation by Dr. Trinity Bivalacqua discussing updated clinical and translational results from BOND-003 cohort C, a phase 3, single-arm study of intravesical cretostimogene grenadenorepvec for high-risk BCG-unresponsive non muscle invasive bladder cancer with CIS. There is a significant unmet need for clinically effective and well-tolerated bladder-sparing treatments in these high risk patients.
Presented by Sia Daneshmand, MD
The 2025 European Association of Urology (EAU) Annual Meeting held in Madrid, Spain between March 21st and 24th 2025, was host to the Abstract Session 05: On the Horizon: Ongoing Trials in Urology. Dr. Sia Daneshmand presented A0083: Trial in Progress: BOND-003 Cohort P- A Multi-national, Single-arm Study of Intravesical Cretostimogene Grenadenorepvec for the Treatment of High-Risk, Papillary Only, BCG-Unresponsive Non-Muscle Invasive Bladder Cancer.
Reno, Nevada (UroToday.com) -- CG Oncology, Inc. (NASDAQ: CGON), a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients with bladder cancer, announced that a late-breaking abstract on BOND-003 Cohort C, as well as three posters highlighting cretostimogene grenadenorepvec, will be presented at the 40th Annual European Association of Urology (EAU) Congress
Presented by Mark Tyson II, MD, MPH
The 2024 SUO annual meeting included a urothelial carcinoma session, featuring a presentation by Dr. Mark Tyson discussing BOND-003 Cohort P, a multi-national, single-arm study of intravesical cretostimogene grenadenorepvec for the treatment of high-risk, papillary only, BCG-unresponsive non muscle invasive bladder cancer (NMIBC).
Presented by Neema Navai, MD
The 2024 South Central AUA annual meeting included a session on bladder cancer, featuring a presentation by Dr. Neema Navai discussing emerging treatments for non muscle invasive bladder cancer (NMIBC). From a historical perspective, Dr. Navai notes that Dr. Raymond Pearl performed a case control autopsy study (controlling for sex, age, and race) in 1929 assessing the rate of tuberculosis, finding that in cancer patients it was 6.6% compared to 16.3% in non-cancer patients. 
Presented by Mark Tyson II, MD, MPH
The 2024 American Urological Association (AUA) annual meeting featured a session on bladder cancer trials in progress, and a presentation by Dr. Mark Tyson discussing BOND-003- Cohort P, a multi-national, single-arm study of intravesical cretostimogene grenadenorepvec for the treatment of high risk, papillary only, BCG-unresponsive non-muscle invasive bladder cancer.
Presented by Mark Tyson II, MD, MPH
The 2024 American Urological Association (AUA) annual meeting featured a plenary session, and a presentation by Dr. Mark Tyson discussing results from BOND-003, a phase 3, single-arm study assessing intravesical cretostimogene grenadenorepvec for the treatment of high risk, BCG-unresponsive non-muscle invasive bladder cancer.
Press Releases
Official Announcements on Clinical Developments
Cretostimogene grenadenorepvec is a serotype-5 oncolytic adenovirus designed to selectively replicate in cancer cells with retinoblastoma pathway alterations, previously tested as monotherapy in bacillus Calmette–Guérin (BCG)-experienced non-muscle-invasive bladder cancer.